Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 14, 2022; 28(26): 3232-3242
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3232
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3232
Figure 2 Shrinkage of the hepatic artery diameters in patient with unresectable hepatocellular carcinoma after treatment with hepatic arterial infusion chemotherapy plus lenvatinib.
A-C: Digital subtraction angiography performed before treatment (A), after 1 (B) and 2 (C) mo of treatment; D-H: Bars represent the vessel diameters before treatment, at 1 and 2 mo after treatment. P-values are calculated using the mixed linear model for repeated measured data. cP < 0.001. NS: Not significant (P > 0.05); CHA: Common hepatic artery; PHA: Proper hepatic artery; LHA: Left hepatic artery; RHA: Right hepatic artery; TFA: Tumor-feeding artery.
- Citation: Wu DD, He XF, Tian C, Peng P, Chen CL, Liu XH, Pang HJ. Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment. World J Gastroenterol 2022; 28(26): 3232-3242
- URL: https://www.wjgnet.com/1007-9327/full/v28/i26/3232.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i26.3232